Drug Metabolism and Bioanalysis Letters

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Research Article

Evaluating the Influence of St. John’s Wort on Naproxen Pharmacokinetics and Pharmacodynamics: A Drug Interaction Assessment

Author(s): Keerthana S. Halumane and Sunil Kumar Kadiri*

Volume 17, Issue 3, 2024

Published on: 27 February, 2025

Page: [137 - 148] Pages: 12

DOI: 10.2174/0118723128356859250220063938

Price: $65

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease which leads to pain and disability that may trigger anxiety and sleep disturbances. Naproxen and St. John’s Wort concomitant administration in RA and anxiety raises the question of safety due to a potential drug interaction.

Materials and Methods: Albino Wistar rats were treated with naproxen and St. John’s Wort for 30 days. The study involved the evaluation of safety of naproxen when combined with St. John’s Wort by estimation of biochemical markers such as SGOT, SGPT, TG’s, Creatinine, BUN, the extent of gastromucosal damage and estimation of AUC, t1/2 and Clearance using blood serum analysis with HPLC after 30 days of treatment. Histopathological studies were also conducted to determine the tissue architecture.

Results: Elevated levels of hepatic markers SGOT, SGPT, TG, and gastro-mucosal damage with enhanced ulcer index were found in naproxen-St. John’s Wort treated rats as compared to only naproxen treated rats. HPLC analysis displayed increased AUC and t1/2 of naproxen with decreased clearance in naproxen-St. John’s Wort treated rats. Histopathological findings revealed tissue rupture and mucosal damage supporting the naproxen toxicity.

Conclusion: Consulting a healthcare professional before combining St. John's Wort with naproxen is essential to assess potential risks, manage drug interactions, and ensure safety. Personalized advice helps optimize treatment outcomes for both rheumatoid arthritis and mental health.

Keywords: Naproxen, St. John’s Wort, biochemical markers, gastromucosal, drug interactions, NSAID, rheumatoid arthritis.

[1]
Anderson, L.L.; Berns, E.J.; Bugga, P.; George, A.L., Jr; Mrksich, M. Measuring drug metabolism kinetics and drug–drug interactions using self-assembled monolayers for matrix-assisted laser desorption-ionization mass spectrometry. Anal. Chem., 2016, 88(17), 8604-8609.
[http://dx.doi.org/10.1021/acs.analchem.6b01750] [PMID: 27467208]
[2]
Bushra, R.; Aslam, N.; Khan, A. Food-drug interactions. Oman Med. J., 2011, 26(2), 77-83.
[http://dx.doi.org/10.5001/omj.2011.21] [PMID: 22043389]
[3]
Pontelo, B.M.; Greco, D.B.; Guimarães, N.S.; Rotsen, N.; Braga, V.A.R.; Pimentel, P.H.N.; Barbosa, H.; Barroso, T.M.; Tupinambás, U. Profile of drug-drug interactions and impact on the effectiveness of antiretroviral therapy among patients living with HIV followed at an Infectious Diseases Referral Center in Belo Horizonte, Brazil. Braz. J. Infect. Dis., 2020, 24(2), 104-109.
[http://dx.doi.org/10.1016/j.bjid.2020.03.006] [PMID: 32360120]
[4]
Koziolek, M.; Alcaro, S.; Augustijns, P.; Basit, A.W.; Grimm, M.; Hens, B.; Hoad, C.L.; Jedamzik, P.; Madla, C.M.; Maliepaard, M.; Marciani, L.; Maruca, A.; Parrott, N.; Pávek, P.; Porter, C.J.H.; Reppas, C.; van Riet-Nales, D.; Rubbens, J.; Statelova, M.; Trevaskis, N.L.; Valentová, K.; Vertzoni, M.; Čepo, D.V.; Corsetti, M. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. Eur. J. Pharm. Sci., 2019, 134, 31-59.
[http://dx.doi.org/10.1016/j.ejps.2019.04.003] [PMID: 30974173]
[5]
Rodrigues, M.C.S.; Oliveira, C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: An integrative review. Rev. Lat. Am. Enfermagem, 2016, 24, e2800.
[http://dx.doi.org/10.1590/1518-8345.1316.2800]
[6]
Gu, Q. Prescription drug use continues to increase: US prescription drug data for 2007-2008; US Department of Health and Human Services, 2010.
[7]
Palleria, C.; Di Paolo, A.; Giofrè, C.; Caglioti, C.; Leuzzi, G.; Siniscalchi, A.; De Sarro, G.; Gallelli, L. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci., 2013, 18(7), 601-610.
[PMID: 24516494]
[8]
Abdo, M.S.; Hammad, M.A.; Harun, S.N.; Eusoff, T.M.; Ghadzi, S.M.S. Evaluation of knowledge, attitude and practice of healthcare providers towards lifethreatening drug-drug interactions in Penang General Hospital, Malaysia. Clin. Epidemiol. Glob. Health, 2020, 8, 1253-1258.
[http://dx.doi.org/10.1016/j.cegh.2020.04.023]
[9]
Wójcikowski, J.; Danek, P.J.; Basińska-Ziobroń, A.; Pukło, R.; Daniel, W.A. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: A prediction of possible drug-drug interactions. Pharmacol. Rep., 2020, 72(3), 612-621.
[10]
Zhang, D.; Zhu, M.; Humphreys, W.G. Drug Metabolism in Drug Design and Development: BASIC Concepts and Practice; John Wiley & Sons, 2007.
[http://dx.doi.org/10.1002/9780470191699]
[11]
Lee, D.M.; Weinblatt, M.E. Rheumatoid arthritis. Lancet, 2001, 358(9285), 903-911.
[http://dx.doi.org/10.1016/S0140-6736(01)06075-5] [PMID: 11567728]
[12]
Díaz-González, F.; Hernández-Hernández, M.V. Rheumatoid arthritis. Med. Clin., 2023, 161(12), 533-542.
[http://dx.doi.org/10.1016/j.medcle.2023.07.008]
[13]
Radu, A.F.; Bungau, S.G. Management of Rheumatoid arthritis: An overview. Cells, 2021, 10(11), 2857.
[http://dx.doi.org/10.3390/cells10112857] [PMID: 34831081]
[14]
Brown, P.; Pratt, A.G.; Hyrich, K.L. Therapeutic advances in rheumatoid arthritis. BMJ, 2024, 384, e070856.
[http://dx.doi.org/10.1136/bmj-2022-070856] [PMID: 38233032]
[15]
Scott, D.L.; Wolfe, F.; Huizinga, T.W. Artritisreumatoide. Lancet, 2010, 376(9746), 1094-1098.
[http://dx.doi.org/10.1016/S0140-6736(10)60826-4] [PMID: 20870100]
[16]
Karatas, G.; Bal, A.; Yuceege, M.; Yalcin, E.; Firat, H.; Dulgeroglu, D.; Karataş, F.; Sahin, S.; Cakci, A.; Ardic, S. The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in Rheumatoid arthritis patients. Clin. Rheumatol., 2017, 36(1), 45-50.
[http://dx.doi.org/10.1007/s10067-016-3387-6] [PMID: 27567629]
[17]
Sostres, C.; Gargallo, C.J.; Arroyo, M.T.; Lanas, A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol., 2010, 24(2), 121-132.
[http://dx.doi.org/10.1016/j.bpg.2009.11.005] [PMID: 20227026]
[18]
Smith, J.B.; Haynes, M.K. Rheumatoid arthritis--A molecular understanding. Ann. Intern. Med., 2002, 136(12), 908-922.
[http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00012] [PMID: 12069565]
[19]
Köhler, O.; Benros, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 2014, 71(12), 1381-1391.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.1611] [PMID: 25322082]
[20]
McInnes, I.B.; Schett, G. The pathogenesis of Rheumatoid arthritis. N. Engl. J. Med., 2011, 365(23), 2205-2219.
[http://dx.doi.org/10.1056/NEJMra1004965] [PMID: 22150039]
[21]
Rainsford, K.D. Pharmacology and Toxicology of COX-2 Inhibitors. InCOX-2 Inhibitors; Birkhäuser Basel: Basel, 2004, pp. 67-131.
[22]
Patiño-Camacho, S.I.; Moreno, M.G.L.; Flores-Murrieta, F.J.; Déciga-Campos, M. The pharmacokinetic profile of the combination of naproxen and tizanidine in rat. Drug Dev. Res., 2013, 74(1), 31-37.
[http://dx.doi.org/10.1002/ddr.21053]
[23]
Sehonova, P.; Plhalova, L.; Blahova, J.; Doubkova, V.; Prokes, M.; Tichy, F.; Fiorino, E.; Faggio, C.; Svobodova, Z. Toxicity of naproxen sodium and its mixture with tramadol hydrochloride on fish early life stages. Chemosphere, 2017, 188, 414-423.
[http://dx.doi.org/10.1016/j.chemosphere.2017.08.151] [PMID: 28898774]
[24]
Malhi, G.S.; Mann, J.J. Depression. Lancet, 2018, 392(10161), 2299-2312.
[http://dx.doi.org/10.1016/S0140-6736(18)31948-2] [PMID: 30396512]
[25]
Nair, A.; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7(2), 27-31.
[http://dx.doi.org/10.4103/0976-0105.177703] [PMID: 27057123]
[26]
Duval, F.; Lebowitz, B.D.; Macher, J.P. Treatments in depression. Dialogues Clin. Neurosci., 2006, 8(2), 191-206.
[http://dx.doi.org/10.31887/DCNS.2006.8.2/fduval] [PMID: 16889105]
[27]
Carazo, A.; Dusek, J.; Holas, O.; Skoda, J.; Hyrsova, L.; Smutny, T.; Soukup, T.; Dosedel, M.; Pávek, P. Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front. Pharmacol., 2018, 9, 993.
[http://dx.doi.org/10.3389/fphar.2018.00993] [PMID: 30364229]
[28]
Fekete, F.; Menus, Á.; Tóth, K.; Kiss, Á.F.; Minus, A.; Sirok, D.; Belič, A.; Póti, Á.; Csukly, G.; Monostory, K. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Sci. Rep., 2023, 13(1), 18507.
[http://dx.doi.org/10.1038/s41598-023-45752-6] [PMID: 37898643]
[29]
Denisov, I.G.; Makris, T.M.; Sligar, S.G.; Schlichting, I. Structure and chemistry of cytochrome P450. Chem. Rev., 2005, 105(6), 2253-2278.
[http://dx.doi.org/10.1021/cr0307143] [PMID: 15941214]
[30]
Pelkonen, O.; Nebert, D.W. Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. Pharmacol. Rev., 1982, 34(2), 189-222.
[PMID: 6287505]
[31]
Zhou, S.F.; Yang, L.P.; Zhou, Z.W.; Liu, Y.H.; Chan, E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J., 2009, 11(3), 481-494.
[http://dx.doi.org/10.1208/s12248-009-9127-y] [PMID: 19590965]
[32]
van Delft, M.A.M.; Verheul, M.K.; Burgers, L.E.; Derksen, V.F.A.M.; van der Helm-van Mil, A.H.M.; van der Woude, D.; Huizinga, T.W.J.; Toes, R.E.M.; Trouw, L.A. The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Res. Ther., 2017, 19(1), 190.
[http://dx.doi.org/10.1186/s13075-017-1392-z] [PMID: 28810902]
[33]
Guengerich, F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol., 2008, 21(1), 70-83.
[http://dx.doi.org/10.1021/tx700079z] [PMID: 18052394]
[34]
Seist, G. Need for pharmacogenomic information also for generic medications: Recommendation of the European Society of Pharmacogenomics and Theranostics (ESPT). dmdi, 2012, 27(2), 119.
[http://dx.doi.org/10.1515/dmdi-2012-0010] [PMID: 22706235]
[35]
Manikandan, P.; Nagini, S. Cytochrome P450 structure, function and clinical significance: A review. Curr. Drug Targets, 2018, 19(1), 38-54.
[PMID: 28124606]
[36]
Borrelli, F.; Izzo, A.A. Herb-drug interactions with St John’s wort (Hypericum perforatum): An update on clinical observations. AAPS J., 2009, 11(4), 710-727.
[http://dx.doi.org/10.1208/s12248-009-9146-8] [PMID: 19859815]
[37]
Novelli, M.; Masiello, P.; Beffy, P.; Menegazzi, M. Protective role of St. John’s wort and its components hyperforin and hypericin against diabetes through inhibition of inflammatory signaling: Evidence from in vitro and in vivo studies. Int. J. Mol. Sci., 2020, 21(21), 8108.
[http://dx.doi.org/10.3390/ijms21218108] [PMID: 33143088]
[38]
Tedeschi, E.; Menegazzi, M.; Margotto, D.; Suzuki, H.; Forstermann, U.; Kleinert, H. Anti-inflammatory actions of St John’s wort: Inhibition of human iNOS expression by down regulating STAT-1 α activation. J. Pharmacol. Exp. Ther., 2003, 307, 254-261.
[http://dx.doi.org/10.1124/jpet.103.054460]
[39]
Kamalian, A.; Asl, M.S.; Dolatshahi, M.; Afshari, K.; Shamshiri, S.; Roudsari, N.M.; Momtaz, S.; Rahimi, R.; Abdollahi, M.; Abdolghaffari, A.H. Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways. World J. Gastroenterol., 2020, 26(24), 3365-3400.
[http://dx.doi.org/10.3748/wjg.v26.i24.3365] [PMID: 32655263]
[40]
Verre, J.; Boisson, M.; Paumier, A.; Tribolo, S.; Boujedaini, N. Anti-inflammatory effects of Arnica montana (mother tincture and homeopathic dilutions) in various cell models. J. Ethnopharmacol., 2024, 318(Pt B), 117064.
[http://dx.doi.org/10.1016/j.jep.2023.117064] [PMID: 37598770]

Rights & Permissions Print Cite
© 2026 Bentham Science Publishers | Privacy Policy